Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

ELMD vs LNTH vs MDT vs RMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ELMD
Electromed, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$222M
5Y Perf.+86.3%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+562.8%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-20.9%
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.15B
5Y Perf.+28.7%

ELMD vs LNTH vs MDT vs RMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ELMD logoELMD
LNTH logoLNTH
MDT logoMDT
RMD logoRMD
IndustryMedical - DevicesDrug Manufacturers - Specialty & GenericMedical - DevicesMedical - Instruments & Supplies
Market Cap$222M$5.92B$99.94B$30.15B
Revenue (TTM)$69M$1.55B$35.48B$5.54B
Net Income (TTM)$9M$279M$4.61B$1.52B
Gross Margin78.2%60.5%61.9%61.7%
Operating Margin16.7%18.8%17.9%34.3%
Forward P/E24.4x17.5x14.1x18.8x
Total Debt$198K$738K$28.52B$852M
Cash & Equiv.$15M$359M$2.22B$1.21B

ELMD vs LNTH vs MDT vs RMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ELMD
LNTH
MDT
RMD
StockMay 20May 26Return
Electromed, Inc. (ELMD)100186.3+86.3%
Lantheus Holdings, … (LNTH)100662.8+562.8%
Medtronic plc (MDT)10079.1-20.9%
ResMed Inc. (RMD)100128.7+28.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: ELMD vs LNTH vs MDT vs RMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Electromed, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. RMD also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ELMD
Electromed, Inc.
The Growth Play

ELMD is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 17.0%, EPS growth 48.3%, 3Y rev CAGR 15.4%
  • 17.0% revenue growth vs LNTH's 0.5%
  • +22.1% vs RMD's -14.5%
Best for: growth exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 41.9% 10Y total return vs ELMD's 482.6%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
Best for: long-term compounding and sleep-well-at-night
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Beta 0.47, yield 3.6%, current ratio 1.85x
  • Lower P/E (14.1x vs 24.4x)
  • Beta 0.47 vs ELMD's 1.03
Best for: income & stability and defensive
RMD
ResMed Inc.
The Value Pick

RMD is the clearest fit if your priority is valuation efficiency.

  • PEG 1.08 vs MDT's 36.00
  • 27.4% margin vs MDT's 13.0%
Best for: valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthELMD logoELMD17.0% revenue growth vs LNTH's 0.5%
ValueMDT logoMDTLower P/E (14.1x vs 24.4x)
Quality / MarginsRMD logoRMD27.4% margin vs MDT's 13.0%
Stability / SafetyMDT logoMDTBeta 0.47 vs ELMD's 1.03
DividendsMDT logoMDT3.6% yield, 36-year raise streak, vs RMD's 1.0%, (2 stocks pay no dividend)
Momentum (1Y)ELMD logoELMD+22.1% vs RMD's -14.5%
Efficiency (ROA)MDT logoMDT175.8% ROA vs LNTH's 12.4%, ROIC 6.0% vs 30.6%

ELMD vs LNTH vs MDT vs RMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ELMDElectromed, Inc.
FY 2024
Home Care
50.4%$841,000
Other
49.6%$826,000
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B
RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M

ELMD vs LNTH vs MDT vs RMD — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGLNTH

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 515.3x ELMD's $69M. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to MDT's 13.0%. On growth, ELMD holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
RevenueTrailing 12 months$69M$1.5B$35.5B$5.5B
EBITDAEarnings before interest/tax$12M$347M$9.4B$2.1B
Net IncomeAfter-tax profit$9M$279M$4.6B$1.5B
Free Cash FlowCash after capex$9M$372M$5.4B$1.8B
Gross MarginGross profit ÷ Revenue+78.2%+60.5%+61.9%+61.7%
Operating MarginEBIT ÷ Revenue+16.7%+18.8%+17.9%+34.3%
Net MarginNet income ÷ Revenue+13.1%+18.0%+13.0%+27.4%
FCF MarginFCF ÷ Revenue+13.4%+24.0%+15.2%+31.7%
Rev. Growth (YoY)Latest quarter vs prior year+16.3%+1.2%+8.8%+10.8%
EPS Growth (YoY)Latest quarter vs prior year+45.5%+76.5%-11.9%+9.3%
RMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 5 of 7 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 31% valuation discount to ELMD's 31.2x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
Market CapShares × price$222M$5.9B$99.9B$30.1B
Enterprise ValueMkt cap + debt − cash$207M$5.6B$126.2B$29.8B
Trailing P/EPrice ÷ TTM EPS31.23x26.69x21.60x21.76x
Forward P/EPrice ÷ next-FY EPS est.24.42x17.52x14.13x18.78x
PEG RatioP/E ÷ EPS growth rate2.43x36.00x1.25x
EV / EBITDAEnterprise value multiple19.14x14.61x14.32x15.51x
Price / SalesMarket cap ÷ Revenue3.47x3.84x2.98x5.86x
Price / BookPrice ÷ Book value/share5.42x5.72x2.08x5.11x
Price / FCFMarket cap ÷ FCF20.06x16.73x19.28x18.14x
MDT leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

RMD leads this category, winning 4 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $9 for MDT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs LNTH's 5/9, reflecting strong financial health.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
ROE (TTM)Return on equity+19.8%+24.3%+9.4%+24.4%
ROA (TTM)Return on assets+16.4%+12.4%+175.8%+18.0%
ROICReturn on invested capital+25.6%+30.6%+6.0%+22.8%
ROCEReturn on capital employed+22.0%+17.1%+7.5%+25.7%
Piotroski ScoreFundamental quality 0–97568
Debt / EquityFinancial leverage0.00x0.00x0.59x0.14x
Net DebtTotal debt minus cash-$15M-$358M$26.3B-$358M
Cash & Equiv.Liquid assets$15M$359M$2.2B$1.2B
Total DebtShort + long-term debt$198,000$738,000$28.5B$852M
Interest CoverageEBIT ÷ Interest expense11.72x9.08x66.06x
RMD leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — ELMD and LNTH each lead in 3 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $7,230 for MDT. Over the past 12 months, ELMD leads with a +22.1% total return vs RMD's -14.5%. The 3-year compound annual growth rate (CAGR) favors ELMD at 34.7% vs RMD's -2.9% — a key indicator of consistent wealth creation.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
YTD ReturnYear-to-date-1.9%+35.3%-18.1%-15.2%
1-Year ReturnPast 12 months+22.1%+13.1%-2.8%-14.5%
3-Year ReturnCumulative with dividends+144.6%-4.0%-4.2%-8.4%
5-Year ReturnCumulative with dividends+178.1%+314.2%-27.7%+11.0%
10-Year ReturnCumulative with dividends+482.6%+4192.5%+26.5%+293.8%
CAGR (3Y)Annualised 3-year return+34.7%-1.4%-1.4%-2.9%
Evenly matched — ELMD and LNTH each lead in 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than ELMD's 1.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs RMD's 70.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
Beta (5Y)Sensitivity to S&P 5001.03x0.47x0.47x0.66x
52-Week HighHighest price in past year$30.73$93.00$106.33$293.81
52-Week LowLowest price in past year$17.73$47.25$77.16$198.64
% of 52W HighCurrent price vs 52-week peak+87.4%+97.8%+73.3%+70.4%
RSI (14)Momentum oscillator 0–10056.561.227.335.6
Avg Volume (50D)Average daily shares traded41K886K7.8M1.1M
Evenly matched — LNTH and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: ELMD as "Buy", LNTH as "Buy", MDT as "Buy", RMD as "Buy". Consensus price targets imply 41.5% upside for ELMD (target: $38) vs 11.0% for LNTH (target: $101). For income investors, MDT offers the higher dividend yield at 3.57% vs RMD's 1.02%.

MetricELMD logoELMDElectromed, Inc.LNTH logoLNTHLantheus Holdings…MDT logoMDTMedtronic plcRMD logoRMDResMed Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$38.00$101.00$109.50$281.29
# AnalystsCovering analysts4174935
Dividend YieldAnnual dividend ÷ price+3.6%+1.0%
Dividend StreakConsecutive years of raises03614
Dividend / ShareAnnual DPS$2.78$2.11
Buyback YieldShare repurchases ÷ mkt cap+4.5%+5.1%+3.2%+1.0%
MDT leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

RMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.

Best OverallMedtronic plc (MDT)Leads 2 of 6 categories
Loading custom metrics...

ELMD vs LNTH vs MDT vs RMD: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ELMD or LNTH or MDT or RMD a better buy right now?

For growth investors, Electromed, Inc.

(ELMD) is the stronger pick with 17. 0% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Electromed, Inc. (ELMD) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ELMD or LNTH or MDT or RMD?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Electromed, Inc. at 31. 2x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — ELMD or LNTH or MDT or RMD?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ELMD or LNTH or MDT or RMD?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Electromed, Inc. 's 1. 03β — meaning ELMD is approximately 121% more volatile than MDT relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — ELMD or LNTH or MDT or RMD?

By revenue growth (latest reported year), Electromed, Inc.

(ELMD) is pulling ahead at 17. 0% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Electromed, Inc. grew EPS 48. 3% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ELMD or LNTH or MDT or RMD?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 11. 8% for Electromed, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 15. 1% for ELMD. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ELMD or LNTH or MDT or RMD more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 24. 4x for Electromed, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ELMD: 41. 5% to $38. 00.

08

Which pays a better dividend — ELMD or LNTH or MDT or RMD?

In this comparison, MDT (3.

6% yield), RMD (1. 0% yield) pay a dividend. ELMD, LNTH do not pay a meaningful dividend and should not be held primarily for income.

09

Is ELMD or LNTH or MDT or RMD better for a retirement portfolio?

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Both have compounded well over 10 years (RMD: +293. 8%, ELMD: +482. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ELMD and LNTH and MDT and RMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELMD is a small-cap high-growth stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; RMD is a mid-cap quality compounder stock. MDT, RMD pay a dividend while ELMD, LNTH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ELMD

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 8%
  • Net Margin > 7%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ELMD and LNTH and MDT and RMD on the metrics below

Revenue Growth>
%
(ELMD: 16.3% · LNTH: 1.2%)
Net Margin>
%
(ELMD: 13.1% · LNTH: 18.0%)
P/E Ratio<
x
(ELMD: 31.2x · LNTH: 26.7x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.